JP Morgan Chase
BEAM icon

JP Morgan Chase’s Beam Therapeutics BEAM Stock Holding History

JP Morgan Chase’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1M Sell
514,767
-36,588
-7% -$1.1M ﹤0.01% 2307
2026
Q1 		$12.1M Sell
551,355
-67,886
-11% -$1.88M ﹤0.01% 2503
2025
Q4 		$17.2M Buy
619,241
+77,938
+14% +$1.99M ﹤0.01% 2187
2025
Q3 		$13.1M Sell
541,303
-38,996
-7% -$776K ﹤0.01% 2486
2025
Q2 		$9.87M Sell
580,299
-175,022
-23% -$3.05M ﹤0.01% 2559
2025
Q1 		$14.8M Buy
755,321
+241,650
+47% +$6.33M ﹤0.01% 2184
2024
Q4 		$12.7M Sell
513,671
-125,567
-20% -$3.2M ﹤0.01% 2464
2024
Q3 		$15.7M Sell
639,238
-50,827
-7% -$1.31M ﹤0.01% 2206
2024
Q2 		$16.2M Buy
690,065
+224,579
+48% +$5.52M ﹤0.01% 2027
2024
Q1 		$15.4M Sell
465,486
-57,947
-11% -$1.81M ﹤0.01% 2104
2023
Q4 		$14.2M Sell
523,433
-139,122
-21% -$3.46M ﹤0.01% 2135
2023
Q3 		$15.9M Sell
662,555
-45,125
-6% -$1.21M ﹤0.01% 1866
2023
Q2 		$22.6M Sell
707,680
-14,455
-2% -$469K ﹤0.01% 1616
2023
Q1 		$22.1M Sell
722,135
-19,280
-3% -$761K ﹤0.01% 1593
2022
Q4 		$29M Sell
741,415
-13,741
-2% -$615K ﹤0.01% 1406
2022
Q3 		$36M Buy
755,156
+16,296
+2% +$930K 0.01% 1210
2022
Q2 		$28.6M Sell
738,860
-3,809
-0.5% -$151K ﹤0.01% 1358
2022
Q1 		$42.6M Buy
742,669
+9,575
+1% +$628K 0.01% 1257
2021
Q4 		$58.4M Buy
733,094
+106,582
+17% +$9.13M 0.01% 1135
2021
Q3 		$54.5M Buy
626,512
+100,772
+19% +$10.1M 0.01% 1133
2021
Q2 		$67.7M Buy
525,740
+171,252
+48% +$13.6M 0.01% 1082
2021
Q1 		$28.4M Buy
354,488
+120,030
+51% +$11.4M ﹤0.01% 1471
2020
Q4 		$19.1M Buy
234,458
+59,935
+34% +$2.95M ﹤0.01% 1647
2020
Q3 		$4.31M Buy
174,523
+133,594
+326% +$3.31M ﹤0.01% 2693
2020
Q2 		$1.15M Buy
40,929
+743
+2% +$16K ﹤0.01% 3430
2020
Q1 		$723K Buy
+40,186
New +$873K ﹤0.01% 3618

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

JP Morgan Chase's BEAM Position: Q2 2026 in Review

JP Morgan Chase reduced its Beam Therapeutics (BEAM) stake by 6.6% in Q2 2026, selling an estimated $1.1M and leaving 514,767 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

JP Morgan Chase first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $67.7M in Q2 2021. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • JP Morgan Chase held 514,767 shares of Beam Therapeutics worth $18.1M as of Q2 2026.
  • JP Morgan Chase sold 36,588 Beam Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Beam Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2307 holding.
  • JP Morgan Chase first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • JP Morgan Chase's Beam Therapeutics position peaked at $67.7M in Q2 2021.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.